2022年10月31日

贴在凤凰城,亚利桑那州。(2022年11月1日)- CashLabs LLC亚利桑那州图森国家实验室平台为基础,宣布收购生物医学灯塔,亚利桑那州凤凰城建立CLIA认可医疗实验室专注于开发和商业化的早期发现癌症筛查。首席执行官杰森·麦格拉思CashLabs(图片由现金实验室)詹森·麦格拉思CashLabs的CEO说,“收购信标增强我们的使命,为消费者提供简单,准确和负担得起的医疗测试,提高认识和成果。扩大癌症筛查是一个逻辑的延伸我们的测试产品。像我自己结直肠癌(CRC)幸存者,CashLabs热衷于拯救生命通过这种毁灭性疾病的早期检测。“灯塔的测试,是™CRC,是一个简单的、blood-based CLIA实验室开发测试(LDT)结直肠癌筛查临床病例对照研究表明94%的准确性在确定有CRC的存在的风险。灯塔认为血液测试提出了可能的可用性大大增加筛查依从性对CRC的人都不愿意或者没有能力参与筛查与当前推荐fecal-based测试或侵入性成像过程,如结肠镜检查。首席执行官唐韦伯信标生物医学“我们是真正兴奋的一部分CashLabs家庭”唐韦伯说,灯塔的首席执行官。“增加访问的公司的共同愿景CRC筛查是一个完美的组合。CashLabs专长和资源将加速我们的计划积极影响生活。“韦伯将继续担任首席执行官生物医学灯塔。 CashLabs will support Beacon’s in-clinic expansion beyond the state of Arizona while also accelerating the Be-Screened direct-to-consumer test offering. About CashLabs, LLC CashLabs is a national laboratory platform and wellness community that offers a robust menu of at-home and in-clinic healthcare tests. The company offers direct-to-consumer testing kits including food sensitivity, testosterone, and Vitamin D, among others. CashLabs provides consumers the convenience of testing in the comfort of their home or with their physician. The CashLabs community seeks to empower and connect people in better understanding and improving their personal health and quality of life. For more information, visit www.cashlabs .com. About Beacon Biomedical Inc. Beacon Biomedical Inc. is a CLIA accredited proteomic diagnostics laboratory focused on developing and commercializing laboratory developed tests and point-of-care CLIA waived tests for earlier cancer detection. The company’s lead product, BeScreened™-CRC, is a blood-based test for the early detection of colorectal cancer. Beacon’s product development pipeline includes early detection assays for breast, lung, and prostate cancers. For more information, visit www.beaconbiomedical.com .